跳至主要内容
临床试验/NCT04809246
NCT04809246已完成不适用

Prisons Evaluation of a One-stop-shop InterVentiOn to Scale-up Hepatitis C Testing and Treatment (PIVOT)

Kirby Institute2 个研究点 分布在 1 个国家目标入组 541 人开始时间: 2019年10月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
541
试验地点
2
主要终点
The proportion of people who have initiated DAA therapy within 12 weeks from enrolment

研究概览

简要总结

A prospective historically controlled study to assess the effect of an intervention integrating point-of-care hepatitis C (HCV) RNA testing, non-invasive liver fibrosis assessment, fast-tracked direct-acting antiviral (DAA) prescription, and linkage to hepatitis care (a 'one-stop-shop' intervention), on the proportion of participants initiating DAA therapy among people who are recently incarcerated within reception correctional centre(s) in Australia.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The proportion of people who have initiated DAA therapy within 12 weeks from enrolment

时间窗: 12 weeks from enrolment

次要结局

  • The proportion of people who have an end of treatment response(End of Treatment (8 weeks from treatment initiation))
  • The acceptability of the 'one-stop-shop' (proportion of prisoners who refuse to participate)(Varying, up to end of subject enrolment (estimated to be 12 months from study commencement))
  • The proportion of people reinfected at SVR12(Varying, up to 9 months post-enrolment.)
  • The proportion of people lost to follow-up(Varying, up to end of study (estimated to be 12 months from study commencement))
  • The proportion of participants who complete DAA therapy in prison(End of Treatment (8 weeks from treatment initiation))
  • The cost-effectiveness of the 'one-stop-shop' (cost-ratio of 'one-stop-shop' and standard of care)(End of study (estimated to be 12 months from study commencement))
  • The proportion of people tested for HCV infection at 12 weeks from enrolment(12 weeks from enrolment)
  • The proportion of people who have an HCV treatment response (sustained virological response)(Sustained virological response at 12 weeks post treatment completion)
  • The time taken from testing to each step in the care cascade(Varying, up to 9 months post-enrolment.)
  • The proportion of people reporting injecting risk behaviours (at ETR and SVR12)(Varying, up to 9 months post-enrolment.)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Prisons Evaluation of a One-stop-shop InterVentiOn | 临床试验